Tag Archives: bad-request

Regeneron/Sanofi Cholesterol Drug Wins FDA Panel Vote

An FDA advisory committee voted 13 to 3 late Tuesday in favor of approving cholesterol buster Praluent, though lingering questions remained about just how many people it will treat. Praluent, from the team-up of Regeneron Pharmaceuticals (REGN) and Sanofi (SNY), is due for a final decision on approval by July 31. Analysts expect multibillion-dollar annual sales eventually. While this would be significant even for big pharma Sanofi, it’s so crucial

3 Fast-Growing Health Care Outsourcers Holding Up

It can take years for big pharma, biotech and medical device firms to bring a product to market. Contract research organizations (CROs) make a life a lot easier for them, providing outsourced research services. It’s all about speed in these industries, and CROs help customers bring products to market faster. IBD’s Medical-Research Equipment/Services industry group has been rising steadily through IBD’s 197 industry group rankings, from a ranking

Verizon could be buyer if Sprint sells spectrum

Verizon Communications (VZ) looms as a buyer if Sprint (S) sells some of its radio spectrum to raise cash for a network upgrade that it badly needs to stay competitive in the U.S. wireless market. “For a company that we expect to burn through another $4.5 billion in cash this calendar year, selling some 2.5 GHz spectrum would certainly provide some level of near-term relief,” said Craig Moffett, an analyst at MoffettNathanson, in a blog post. Verizon and cable TV companies loom as possible buyers of a chunk of Sprint’s spectrum, most of which is in the high frequency of 2.5 gigahertz, says Moffett. Sprint obtained a 120 MHz swath of airwaves in the 2.5 GHz spectrum band through its 2013 acquisition of Clearwire. Sprint outbid Dish Network (DISH) for Clearwire. Wireless networks in higher-frequency bands require more expensive network gear as well as more radio antennas, which is one…